Official ESCRS | European Society of Cataract & Refractive Surgeons
London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical efficacy and short-term safety profile of intravitreal dexamethasone implant in the treatment of macular oedema secondary to retinal vein occlusion

Poster Details

First Author: W.Gan UK

Co Author(s):    A. Jain              

Abstract Details


Macular oedema is the most common sight-threatening complication in retinal vein occlusion. Until recent years the standard treatment for persistent macular oedema was observation for central retinal vein occlusion and grid laser photocoagulation for branch retinal vein occlusion. The development of sustained-release intravitreal dexamethasone implants (Ozurdex®) offers a promising treatment option for patients to preserve vision. With our study, we aim to assess the improvements in visual outcomes as well as the reduction in central retinal thickness, and also to ascertain any clinically significant complications following intravitreal dexamethasone treatment.


The Ophthalmology Department at The Royal Oldham Hospital and Rochdale Infirmary, Manchester, United Kingdom.


The study design was a retrospective cohort study. A consecutive 30 patients (30 eyes) with the diagnosis of macular oedema secondary to either central or branch retinal vein occlusion who had received intravitreal dexamethasone implants between January 2013 and September 2014 were identified from the day case admission database. Data were extracted from the clinical records of included patients, including age, sex and diagnosis. Ocular status before and after treatment including best-corrected visual acuity, central retinal thickness and intraocular pressure was assessed. Details of any clinically significant complications were also noted.


8 (26.7%) patients demonstrated improvement in best-corrected visual acuity (BCVA) of ≥ LogMAR 0.3 from baseline following dexamethasone treatment. Mean decrease in central retinal thickness was 253µm. Adverse effects reported include raised intraocular pressure (6), conjunctival hyperemia (2), eye pain (2) and grey vision (1). No cases of retinal complications or enophthalmitis were observed. The results were comparable to the outcomes in the GENEVA study.


Dexamethasone implants are generally safe and effective for the treatment of macular oedema secondary to non-ischemic retinal vein occlusion. Special considerations should be taken in patients with known history of glaucoma or ocular hypertension. Treatment should be commenced promptly following diagnosis for satisfactory visual outcome.

Financial Disclosure:


Back to Poster listing